Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M

Jazz Pharmaceuticals plc

Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.
Avadel gets immediate license for Lumryz in narcolepsy; license for other indications starts March 1, 2028.
Avadel will pay 3.85% royalty on narcolepsy Lumryz sales (starting Oct 1, 2025) and 10% on other indications.
Jazz expects ~$90M pre-tax charge in Q3 2025, funded with cash on hand.
Jazz denies all alleged wrongdoing; both parties dismiss pending legal proceedings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.